Innate Pharma SA ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Innate Pharma SA ' Product Pipeline Review ' 2012
Published on December 2012

Report Summary


Summary

Global Market Direct's pharmaceuticals report, "Innate Pharma SA - Product Pipeline Review - 2012" provides data on the Innate
Pharma SA's research and development focus. The report includes information on current developmental pipeline, complete with
latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Innate Pharma SA's
corporate website, SEC filings, investor presentations and featured press releases, both from Innate Pharma SA and industry-specific
third party sources, put together by Global Markets Direct's team.

Scope

- Innate Pharma SA - Brief Innate Pharma SA overview including business description, key information and facts, and its locations
and subsidiaries.
- Review of current pipeline of Innate Pharma SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Innate Pharma SA with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Innate Pharma SA's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Innate Pharma SA's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Innate Pharma SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Innate Pharma SA's R&D portfolio and develop key strategic initiatives to
reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Innate Pharma SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Innate Pharma SA and identify potential opportunities in those areas.

Innate Pharma SA ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/7


Table of Content

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Innate Pharma SA Snapshot 6
Innate Pharma SA Overview 6
Key Information 6
Key Facts 6
Innate Pharma SA ' Research and Development Overview 7
Key Therapeutic Areas 7
Innate Pharma SA ' Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products ' Monotherapy 11
Pipeline Products ' Combination Treatment Modalities 12
Innate Pharma SA ' Pipeline Products Glance 13
Innate Pharma SA Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Innate Pharma SA ' Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Innate Pharma SA ' Drug Profiles 17
Discovery 1 Program For Cancer And Inflammation 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Discovery 2 Program For Cancer 18
R&D Progress 18
Discovery 3 Program For Cancer 19
R&D Progress 19
Discovery 4 Program Targeting NKp46 For Cancer And Inflammation 20
R&D Progress 20
IPH-2101 21
R&D Progress 21
IPH-33 23



R&D Progress 23
IPH-41 24
R&D Progress 24
IPH2101 + Revlimid 25
R&D Progress 25
Innate Pharma SA ' Pipeline Analysis 27
Innate Pharma SA ' Pipeline Products by Therapeutic Class 27
Innate Pharma SA ' Pipeline Products by Route of Administration 28
Innate Pharma SA ' Pipeline Products By Mechanism of Action 29
Innate Pharma SA ' Recent Pipeline Updates 30
Innate Pharma SA - Dormant Projects 31
Innate Pharma SA - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
IPH-3102 32
IPH-3201 32
IPH-4201 32
Innate Pharma SA ' Locations And Subsidiaries 33
Head Office 33
Innate Pharma SA, Recent Developments 34
Innate Pharma SA- Press Release 34
Oct 18, 2012: Innate Pharma Announces Publication Of Phase I Trial Results Of IPH2101 In AML In Blood journal 34
Nov 18, 2009: Innate Pharma Initiates Collaboration With Celgene To Evaluate Revlimid Combined With IPH 2101 In Multiple
Myeloma 35
Nov 02, 2009: Innate Pharma Receives Approval From AFSSaPS (The French Regulatory Authorities) To Start An Extension Of The
Phase I Clinical Trial With IPH 2101 35
Sep 21, 2009: Innate Pharma Reports Final Results From Phase IIa Blood Cancer Trial 36
Sep 21, 2009: Innate Pharma Reports Interim Data From Phase I/II Clinical Trial In Follicular Non-Hodgkin's Lymphoma 37
Sep 21, 2009: Innate Pharma Reports Phase II Clinical Data With IPH 1101 In Oncology 37
Aug 27, 2009: Innate Pharma Receives Approval From AFSSaPS (The French Regulatory Authorities) To start A Phase IIa Clinical
Trial With IPH 2101 39
Jun 29, 2009: Innate Pharma Reports Positive Phase IIa Clinical Results For IPH 1101 In Type C Viral Hepatitis 39
May 29, 2009: Innate Pharma Reports Preliminary Phase I Clinical Data For IPH 2101 At The Asco Meeting 40
Financial Deals Landscape 41
Innate Pharma SA, Deals Summary 41
Innate Pharma SA, Pharmaceuticals & Healthcare, Deal Details 42
Partnerships 42
Innate Pharma And Transgene Form Platine Pharma Services 42
Innate Pharma Enters Into Research Agreement With Inserm Transfert 43
Vivalis Enters Into Co-Development Agreement With Innate Pharma 44
Innate Pharma Amends Partnership With Novo Nordisk 45
Innate Pharma Signs An Agreement With Clinical Data 46
Innate Pharma Enters Into Co-Development Agreement With Institut de cancérologie Gustave-Roussy 47
Novo Nordisk Signs Agreement With Innate Pharma 48



Licensing Agreements 49
Bristol-Myers Squibb Enters Into Licensing Agreement With Innate Pharma For IPH2102 49
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 51
Novo Nordisk Enters Into Licensing Agreement With Innate Pharma 53
Cancer Research Technology Enters Into Licensing Agreement With Innate Pharma 54
Equity Offering 55
Innate Pharma Announces Private Placement 55
Innate Pharma Completes Private Placement Of $35 Million 56
Innate Pharma Completes Private Placement Upon Exercise Of Warrants 58
Innate Pharma Completes IPO For $42 Milion 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables

Innate Pharma SA, Key Information 6
Innate Pharma SA, Key Facts 6
Innate Pharma SA ' Pipeline by Indication, 2012 9
Innate Pharma SA ' Pipeline by Stage of Development, 2012 10
Innate Pharma SA ' Monotherapy Products in Pipeline, 2012 11
Innate Pharma SA ' Combination Treatment Modalities in Pipeline, 2012 12
Innate Pharma SA ' Phase II, 2012 13
Innate Pharma SA ' Phase I, 2012 14
Innate Pharma SA ' Pre-Clinical, 2012 15
Innate Pharma SA ' Discovery, 2012 16
Innate Pharma SA ' Pipeline By Therapeutic Class, 2012 27
Innate Pharma SA ' Pipeline By Route of Administration, 2012 28
Innate Pharma SA ' Pipeline Products By Mechanism of Action, 2012 29
Innate Pharma SA ' Recent Pipeline Updates, 2012 30
Innate Pharma SA - Dormant Developmental Projects,2012 31
Innate Pharma SA - Discontinued Pipeline Products, 2012 32
Innate Pharma SA, Deals Summary 41
Innate Pharma And Transgene Form Platine Pharma Services 42
Innate Pharma Enters Into Research Agreement With Inserm Transfert 43
Vivalis Enters Into Co-Development Agreement With Innate Pharma 44
Innate Pharma Amends Partnership With Novo Nordisk 45
Innate Pharma Signs An Agreement With Clinical Data 46
Innate Pharma Enters Into Co-Development Agreement With Institut de cancérologie Gustave-Roussy 47
Novo Nordisk Signs Agreement With Innate Pharma 48
Bristol-Myers Squibb Enters Into Licensing Agreement With Innate Pharma For IPH2102 49



Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 51
Novo Nordisk Enters Into Licensing Agreement With Innate Pharma 53
Cancer Research Technology Enters Into Licensing Agreement With Innate Pharma 54
Innate Pharma Announces Private Placement 55
Innate Pharma Completes Private Placement Of $35 Million 56
Innate Pharma Completes Private Placement Upon Exercise Of Warrants 58
Innate Pharma Completes IPO For $42 Milion 59

List of Figures

Innate Pharma SA ' Pipeline by Indication, 2012 8
Innate Pharma SA ' Pipeline by Stage of Development, 2012 10
Innate Pharma SA ' Monotherapy Products in Pipeline, 2012 11
Innate Pharma SA ' Combination Treatment Modalities in Pipeline, 2012 12
Innate Pharma SA ' Pipeline By Therapeutic Class, 2012 27
Innate Pharma SA - Pipeline Products By Mechanism of Action, 2012 29


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Innate Pharma SA ' Product Pipeline Review ' 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Innate Pharma SA ' Product Pipeline Review ' 2012